SCHEMBL4063479

SCHEMBL4063479

CCOC(=O)C1OC=C(c2cccc(CC(C)NC(=O)OC(C)(C)C)c2)O1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 6/20 0.43
CTSK P43235 5/20 0.43
CTSB P07858 3/20 0.43
CTSL P07711 2/20 0.38
ACE P12821 1/20 0.37
KLK5 Q9Y337 1/20 0.37
TSHR P16473 1/20 0.37
SCN9A Q15858 1/20 0.37
PTPN1 P18031 1/20 0.36
EPHX2 P34913 1/20 0.35
CA2 P00918 1/20 0.35
TACR1 P25103 1/20 0.35
JAK2 O60674 1/20 0.35
S1PR4 O95977 1/20 0.35
F2 P00734 1/20 0.35
LMNA P02545 1/20 0.35
TP53 P04637 1/20 0.35
HPGD P15428 1/20 0.35
XBP1 P17861 1/20 0.35
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4068940 0.82 NFKB1 (0.33) CTSSCTSKCTSBLMNAHSD17B10
SCHEMBL4063474 0.79 ACACB (0.36) CTSSCTSKCTSBCTSLACE
SCHEMBL3050844 0.74 MAPK1 (0.52) CTSSCTSKCTSBCTSLTSHR
SCHEMBL23900516 0.74 JAK2 (0.50) CTSSCTSKCTSBCTSLACE
SCHEMBL2141200 0.72 CTSS (0.48) CTSSCTSKCTSBCTSLACE
SCHEMBL2141206 0.72 CTSS (0.48) CTSSCTSKCTSBCTSLACE
SCHEMBL6028330 0.71 KLK5 (0.48) CTSSCTSKCTSBCTSLACE
SCHEMBL21799327 0.71 CTSL (0.64) CTSSCTSKCTSBCTSLACE
SCHEMBL21583861 0.71 CTSS (0.64) CTSSCTSKCTSBCTSLACE
SCHEMBL4496568 0.71 CTSS (0.64) CTSSCTSKCTSBCTSLACE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7569676-B2 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs ROCHE DIAGNOSTICS OPERATIONS, INC. (US) 2009-08-04 US disclosed
EP-1498415-B1 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs ROCHE DIAGNOSTICS GMBH (DE) 2007-06-27 EP disclosed
US-7060847-B2 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs ROCHE DIAGNOSTICS OPERATIONS, INC. (US) 2006-06-13 US disclosed
US-20050153439-A1 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs GHOSHAL MITALI (US) 2005-07-14 US disclosed
US-20050014210-A1 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs ROCHE DIAGNOSTICS CORPORATION 2005-01-20 US disclosed
EP-1498415-A1 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs Roche Diagnostics GmbH (DE) 2005-01-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014210-A1 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs DRD3, SLC6A3, DRD2 CTSS 1042/4885CTSK 1454/4885CTSB 1274/4885
US-20050153439-A1 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs DRD3, SLC6A3, DRD2 CTSS 1042/4885CTSK 1454/4885CTSB 1274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.